Vyndaqel Market 2026 approaching $4.19 billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Vyndaqel Market By The End Of 2030?

The vyndaqel market has experienced rapid expansion in recent years. Its value is expected to rise from $1.9 billion in 2025 to $2.23 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.4%. The historical increase can be attributed to several factors, including the approval of tafamidis, the limited availability of effective attr-cm treatments, improvements in cardiac imaging diagnostics, the expansion of rare disease programs, and an uptick in cardiology referrals.

The Vyndaqel market size is projected to experience substantial growth in the forthcoming years. It is anticipated to expand to $4.19 billion by 2030, achieving a compound annual growth rate (CAGR) of 17.1%. This projected increase can be ascribed to an aging global population, heightened recognition of amyloid cardiomyopathy, the proliferation of specialty cardiology centers, a surge in genetic testing adoption, and evolving reimbursement support. Prominent trends within the forecast horizon encompass the increasing embrace of transthyretin stabilizers, a rise in the diagnosis of ATTR cardiomyopathy, the development of more oral therapies for rare cardiac ailments, an amplified focus on disease-modifying cardiac drugs, and the extended use of long-term amyloidosis treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21321&type=smp

Which Market Drivers Are Supporting The Expansion Of The Vyndaqel Market?

The increasing embrace of precision medicine is projected to stimulate the expansion of the Vyndaqel market in the future. This approach customizes medical care for individual patients by considering their genetics, environment, and lifestyle, leading to more effective treatments and better results. Its uptake is rising because both patients and medical professionals increasingly favor customized therapies that provide precise treatment and improved management for long-term illnesses. Vyndaqel supports precision medicine by delivering specific treatment for transthyretin amyloidosis (ATTR), thereby guaranteeing that the most suitable patients receive the medication. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) authorized 16 new personalized treatments for rare diseases in 2023, an increase from six in 2022. Consequently, the expanding use of precision medicine is fueling the growth of the Vyndaqel market.

Which Segment Classifications Shape The Vyndaqel Market?

The vyndaqel market covered in this report is segmented –

1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg)

2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

How Are Trends Impacting The Vyndaqel Market?

Leading companies in the vyndaqel market are concentrating on expanding their facilities to produce active pharmaceutical ingredients, such as transthyretin stabilizing therapeutics, aimed at improving cardiovascular outcomes and reducing hospitalization rates for patients with ATTR-CM. A transthyretin stabilizing therapeutic is a pharmacological agent designed to bind and stabilize transthyretin (TTR) tetramers, thereby preventing their breakdown into misfolded monomers that accumulate and form amyloid deposits. For example, in November 2024, BridgeBio Pharma, a US-based biopharmaceutical company focused on genetic diseases, launched Attruby (acoramidis), which is a near-complete (≥90%) transthyretin (TTR) stabilizer developed to address major challenges in transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby (acoramidis) works by binding and stabilizing TTR tetramers, preventing their dissociation into misfolded monomers that form amyloid deposits in cardiac tissue. This treatment offers considerable cardiovascular benefits, including a reduction in cardiovascular death and cardiovascular-related hospitalizations, while also preserving TTR’s natural physiological functions, making it an effective option for enhancing patient outcomes and disease management in ATTR-CM.

Which Companies Are Expanding Their Footprint In The Vyndaqel Market?

Major companies operating in the vyndaqel market are Pfizer Inc.

Read the full vyndaqel market report here:

https://www.thebusinessresearchcompany.com/report/vyndaqel-global-market-report

How Is The Vyndaqel Market Distributed Across Key Geographic Regions?

North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vyndaqel Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21321&type=smp

Browse Through More Reports Similar to the Global Vyndaqel Market 2026, By The Business Research Company

Virtual Assistant Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-assistant-global-market-report

Virtual Data Room Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-data-room-global-market-report

Vulvodynia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795